Post I made on other board regarding Kevetrin:
Post# of 72436
![](/assets/46931549/no_avatar_available_thumb.jpg)
Rotary phones could be bought for $10 or less.
Flip phones went to $30 or so.
Then the iphone came out and it was hundreds of dollars yet it was a massive sales hit. Why? It did what no other phone could do, it basically was a computer inside a phone along with a camera. The public identified it as a great idea and the rest is history.
Quite a similar analogy to Kevetrin in my opinion. What cancer drug on the market today is safe, has next to no side effects, clears the body quickly so it can be taken as a pill multiple times a day, and activates the p53 gene? Not to mention working as a wonderful complementary drug to other cancer treatments.
So what should IPIX expect to get for Kevetrin? This board seems to think we should be paid as if it was a rotary phone (if they don't understand the difference between Kevetrin and other cancer drugs then why the hell are they invested here?) while Leo realizes it could possibly be one of the foundations of future cancer treatment advancements. I side with Leo. Of course, to get to this point we will have to get the pill finalized and tested for safety/efficacy and have many complementary trials run to see how it works with other drugs. That is why Kevetrin is on hold right now and not being shopped for sale or IMO even a partnership. We need to build its value prior to showcasing it for income.
The above has been spelled out ad nauseam but many here still question what is going on regarding Kevetrin. Guess it is over their heads.
We pick up needed money on a small indication of Brilacidin via Oral Mucositis, add in possibly IBD indication if needed, but reserve the big dollar hitters for when we have put more money into them to get vastly more money out of them.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)